BPPV, history of gout associated with Ménière's disease

Published Date: 02 Mar 2023

According to a study published online Dec. 26 in the Journal of Clinical Medicine, a history of gout is associated with an increased risk of benign paroxysmal positional vertigo (BPPV) and Ménière's disease.

Read Full News

Latest News

Adding Radiotherapy to NAC Shows No Survival Benefit in PDAC

For patients with resectable pancreatic cancer, adding radiotherapy to neoadjuvant chemotherapy may improve pathological response, but that doesn’t translate into better outcomes.

Real-World Data Favor Upadacitinib in Bio-Exposed UC

A Portuguese real-world study finds that upadacitinib outperforms tofacitinib and ustekinumab — top-tier options after UC treatment failure — with higher remission rates at 16 and 52 weeks.

FDA Okays RAS Inhibitor Daraxonrasib for Pancreatic Cancer

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients.

FDA Approves Zanidatamab Regimen for HER2-Positive GEA

Zanidatamab with tislelizumab and chemotherapy leads to overall survival of 26.4 months.

Fibermaxxing? Your Microbes (and Your Health) Say Thanks.

Scientists are making progress understanding how a fiber-rich diet can help with chronic disease.

How Strong Is Antioxidants’ Link to Cervical Cancer Risk?

While the rationale behind a beneficial effect of antioxidants on risk has merit, the study’s limitations prevent actionable conclusions.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

For patients with resectable pancreatic cancer, adding radiotherapy to neoadjuvant chemotherapy may improve pathological response, but that doesn’t translate into better outcomes.

A Portuguese real-world study finds that upadacitinib outperforms tofacitinib and ustekinumab — top-tier options after UC treatment failure — with higher remission rates at 16 and 52 weeks.

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients.

Zanidatamab with tislelizumab and chemotherapy leads to overall survival of 26.4 months.

Scientists are making progress understanding how a fiber-rich diet can help with chronic disease.

While the rationale behind a beneficial effect of antioxidants on risk has merit, the study’s limitations prevent actionable conclusions.

News All Time

Iceberg Blamed in Diarrhea Outbreak; Masking Urged in Cities; DEA's Ketamine Probes

Health news and commentary gathered by MedPage Today staff

What's the Best Way to Test for Cyclospora Infection?

Microscopy and DNA tests are both viable, but sensitivity, cost, and availability vary

930 Dead in Outbreak; FDA Backtracks on Iceberg Lettuce; Chronic Cough Drug Fizzles

Health news and commentary gathered by MedPage Today staff

Novel Drug Shows Promise in Crohn's, Ulcerative Colitis

Duvakitug may be suitable for patients previously treated with advanced therapy
HTTP error: 503

Lettuce Supplier Still the Focus in Cyclospora Outbreak, Despite Faulty Test Result

FDA says its investigation and outbreak data continue to point to Taylor Farms' iceberg lettuce

Inside the Intestinal Crypt: Untold Stories of Cyclospora

There's still much to learn about the parasite's past, present, and future

FDA Approves New Blood Test for Colon Cancer Screening

SimpleScreen CRC is indicated for adults 45 and up at average risk
HTTP error: 503HTTP error: 503HTTP error: 503

Michigan Reports First Two U.S. Deaths Related to Diarrhea-Causing Parasite

The CDC says cyclosporiasis is rarely deadly
HTTP error: 503HTTP error: 503

Pancreatic Cancer Vaccine Shows Interception Promise in High-Risk Patients

Durable immune response seen in patients with cancer precursor lesions

Best Gastro Hospitals; GI Bleeding in Jehovah's Witnesses; Steroids for DILI

News and commentary from the world of gastroenterology and hepatology

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

2.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.

3.

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

4.

Spicy Chip Death Lawsuit; Gen X and Cancer; Extreme U.S. Temperatures

5.

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

1.

Effective Management Strategies for Sickle Cell Crisis: Insights from Medical Experts

2.

Public Health Planning for Equitable Access to Advanced Hematology Services

3.

Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA

4.

Comprehensive Applications in Hematology for Better Care

5.

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

3.

Understanding Anemia: Causes and Treatment

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot